A Phase 3 interventional study of BMS-986278 and BMS-986278 Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 390 sites in 33 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 2 of them phase 3. Idiopathic Pulmonary Fibrosis · Bristol-Myers Squibb.
Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 3, and was the 9th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 24 more countries
Bristol-Myers Squibb · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,255 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 100 across the 10 interventional studies, 40 across the 1 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07722507Bristol-Myers SquibbAntifibrotic Therapy Decision-Making in Pulmonary Fibrosis | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278
Drug: BMS-986278
Drug: BMS-986278 Placebo
Specified dose on specified days
Also known as: Admilparant
Specified dose on specified days
Number of participants that experience spontaneous syncopal events
Cohort 1
Time frame: At approximately 4 weeks
Absolute change from baseline in forced vital capacity (FVC) measured in mL
Cohort 2
Time frame: Up to Week 52
Number of participants who discontinued treatment due to any low BP-related Adverse Events
Cohort 1
Time frame: Up to approximately 3 years
Disease progression
Cohort 2 Disease progression will be measured by the time to first disease progression event in at least 1 of the following parameters: * Absolute percent predicted forced vital capacity (ppFVC) decline of ≥ 10% from baseline * Acute exacerbation of pulmonary fibrosis * Respiratory-related hospitalization * All-cause mortality
Time frame: Up to approximately 3 years
Change from baseline in Living with Pulmonary Fibrosis Questionnaire (L-PF) cough domain score
Cohort 2
Time frame: Up to Week 52
Change from baseline in L-PF dyspnea domain score
Cohort 2
Time frame: Up to Week 52
Change from baseline in walking distance measured in 6-minute walk test (6MWT)
Cohort 2
Time frame: Up to Week 52
Time to the first occurrence of any of the components of the composite endpoint: time to first acute exacerbation of pulmonary fibrosis, first Respiratory-related hospitalization, or all-cause mortality
Cohort 2
Time frame: Up to approximately 3 years
Time to absolute percent ppFVC decline of ≥ 10% from baseline
Cohort 2
Time frame: Up to approximately 3 years
Time to first acute exacerbation of pulmonary fibrosis
Cohort 2
Time frame: Up to approximately 3 years
Time to first Respiratory-related hospitalization
Cohort 2
Time frame: Up to approximately 3 years
Time to first pulmonary fibrosis-related hospitalization
Cohort 2
Time frame: Up to approximately 3 years
Time to death
Cohort 2
Time frame: Up to approximately 3 years
Change from baseline in L-PF fatigue domain score
Cohort 2
Time frame: Up to Week 52
Change from baseline in L-PF impacts module score
Cohort 2
Time frame: Up to Week 52
Change from baseline in cough numeric rating scale (NRS)
Cohort 2
Time frame: Up to Week 52
Change from baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) health utility index score
Cohort 2
Time frame: Up to Week 52
Change from baseline in EQ-5D-5L visual analog scale score
Cohort 2
Time frame: Up to Week 52
Rate of decline from baseline in FVC (mL)
Cohort 2
Time frame: Up to Week 52
Rate of decline in ppFVC from baseline
Cohort 2
Time frame: Up to Week 52
Change in ppFVC from baseline
Cohort 2
Time frame: Up to Week 52
Proportion of participants with absolute decline in ppFVC ≥10%
Cohort 2
Time frame: Up to Week 52
Proportion of participants with relative decline in ppFVC ≥10%
Cohort 2
Time frame: Up to Week 52
Change from baseline in single-breath diffusing capacity of the lung for carbon monoxide (DLCO SB) (corrected for hemoglobin) (mL/min/mm Hg)
Cohort 2
Time frame: Up to Week 52
Change in percent predicted single breath diffusing capacity of the lung for carbon monoxide (ppDLCO SB) (corrected for hemoglobin) from baseline
Cohort 2
Time frame: Up to Week 52
Change from baseline in quantitative lung fibrosis (QLF) score via high-resolution computed tomography (HRCT)
Cohort 2
Time frame: Up to Week 52
Number of participants with Adverse Events (AEs)
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of participants with Serious AEs (SAEs)
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of participants with AEs leading to early discontinuation of investigational medicinal product (IMP)
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of participants with AEs related to IMP
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of treatment-emergent deaths
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of participants with clinical laboratory abnormalities
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of participants with electrocardiogram (ECG) abnormalities
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Number of participants with vital sign abnormalities
Cohorts 1 and 2
Time frame: Up to 28 days after last dose
Showing the first 100 of 390 sites across 33 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Sep 2023 (actual). Primary completion is estimated for Oct 2026, 36 months after the start.
Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Admilparant
Idiopathic Pulmonary Fibrosis →